Similar articles for PMID: 28982109

Year	Number of Results
1999	1
2000	1
2001	1
2002	1
2005	3
2006	2
2007	3
2008	3
2009	3
2010	3
2011	6
2012	12
2013	11
2014	11
2015	8
2016	20
2017	10
2018	7
2019	13
2020	11
2021	6
2022	8
2023	4
2024	0

1

Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).

Robert M, Jarlier M, Gourgou S, Desseigne F, Ychou M, Bouché O, Juzyna B, Conroy T, Bennouna J. Robert M, et al. Oncology. 2017;93(6):367-376. doi: 10.1159/000477850. Epub 2017 Oct 6. Oncology. 2017. PMID: 28982109 Clinical Trial.

2

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.

Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L, Hedley DW, Moore MJ, Knox JJ. Chllamma MK, et al. Br J Cancer. 2016 Sep 6;115(6):649-54. doi: 10.1038/bjc.2016.222. Epub 2016 Jul 28. Br J Cancer. 2016. PMID: 27467054 Free PMC article.

3

Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.

Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Orlandi A, et al. Clin Transl Oncol. 2016 Oct;18(10):988-95. doi: 10.1007/s12094-015-1471-z. Epub 2016 Jan 7. Clin Transl Oncol. 2016. PMID: 26742940

4

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. Chiorean EG, et al. Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006. Epub 2016 Jan 22. Ann Oncol. 2016. PMID: 26802160 Free PMC article. Clinical Trial.

5

Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.

Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S, Hauser-Kronberger C, Ulmer H, Greil R. Hohla F, et al. Int J Oncol. 2014 Jan;44(1):319-26. doi: 10.3892/ijo.2013.2176. Epub 2013 Nov 15. Int J Oncol. 2014. PMID: 24247204

6

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T. Gourgou-Bourgade S, et al. J Clin Oncol. 2013 Jan 1;31(1):23-9. doi: 10.1200/JCO.2012.44.4869. Epub 2012 Dec 3. J Clin Oncol. 2013. PMID: 23213101 Clinical Trial.

7

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.

Portal A, Pernot S, Siauve N, Landi B, Lepère C, Colussi O, Rougier P, Zaanan A, Verrière B, Taieb J. Portal A, et al. Clin Res Hepatol Gastroenterol. 2014 Apr;38(2):e23-6. doi: 10.1016/j.clinre.2014.01.005. Epub 2014 Feb 18. Clin Res Hepatol Gastroenterol. 2014. PMID: 24559766

8

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.

Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Hong SM, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Kang J, et al. Invest New Drugs. 2018 Aug;36(4):732-741. doi: 10.1007/s10637-018-0598-5. Epub 2018 Apr 3. Invest New Drugs. 2018. PMID: 29616439

9

Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.

An X, Li YH, Lin XB, Wang FH, Feng F, Xu RH, Jiang WQ, He YJ. An X, et al. Ai Zheng. 2009 Mar;28(3):286-91. Ai Zheng. 2009. PMID: 19619444 Free article.

10

Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.

Lorgis V, Chauffert B, Gentil J, Ghiringhelli F. Lorgis V, et al. Anticancer Res. 2012 Sep;32(9):4125-30. Anticancer Res. 2012. PMID: 22993372

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

132 results

Results by year